Evotec SE (EVO)

Market Cap	1.56B
Revenue (ttm)	844.79M
Net Income (ttm)	-182.89M
Shares Out	177.30M
EPS (ttm)	-1.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	386,320
Open	4.390
Previous Close	3.880
Day's Range	4.360 - 4.470
52-Week Range	2.850 - 12.000
Beta	1.05
Analysts	Buy
Price Target	5.90 (+34.09%)
Earnings Date	Nov 5, 2024

About EVO

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exsci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 4, 2021
• Employees: 5,061
• Stock Exchange: NASDAQ
• Ticker Symbol: EVO
• Website: https://www.evotec.com

Financial Performance

In 2023, Evotec SE's revenue was 781.43 million, an increase of 3.99% compared to the previous year's 751.45 million. Losses were -83.91 million, -52.23% less than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 2 analysts, the average rating for EVO stock is "Buy." The 12-month stock price forecast is $5.9, which is an increase of 34.09% from the latest price.

Price Target

$5.9

(34.09% upside)

Analyst Consensus: Buy